These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28933367)

  • 21. Molecular Mechanism of the Association Between Atrial Fibrillation and Heart Failure Includes Energy Metabolic Dysregulation Due to Mitochondrial Dysfunction.
    Ozcan C; Li Z; Kim G; Jeevanandam V; Uriel N
    J Card Fail; 2019 Nov; 25(11):911-920. PubMed ID: 31415862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elamipretide Improves Mitochondrial Function in the Failing Human Heart.
    Chatfield KC; Sparagna GC; Chau S; Phillips EK; Ambardekar AV; Aftab M; Mitchell MB; Sucharov CC; Miyamoto SD; Stauffer BL
    JACC Basic Transl Sci; 2019 Apr; 4(2):147-157. PubMed ID: 31061916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trimetazidine in cardiovascular medicine.
    Marzilli M; Vinereanu D; Lopaschuk G; Chen Y; Dalal JJ; Danchin N; Etriby E; Ferrari R; Gowdak LH; Lopatin Y; Milicic D; Parkhomenko A; Pinto F; Ponikowski P; Seferovic P; Rosano GMC
    Int J Cardiol; 2019 Oct; 293():39-44. PubMed ID: 31178223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the Mitochondria in Heart Failure: A Translational Perspective.
    Sabbah HN
    JACC Basic Transl Sci; 2020 Jan; 5(1):88-106. PubMed ID: 32043022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Mitochondrial Metabolism to Save the Failing Heart.
    Schenkl C; Heyne E; Doenst T; Schulze PC; Nguyen TD
    Life (Basel); 2023 Apr; 13(4):. PubMed ID: 37109556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic Modulation of Cardiac Metabolism in Heart Failure.
    Rosano GM; Vitale C
    Card Fail Rev; 2018 Aug; 4(2):99-103. PubMed ID: 30206484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term Therapy with Elamipretide.
    Sabbah HN; Gupta RC; Singh-Gupta V; Zhang K; Lanfear DE
    Cardiovasc Drugs Ther; 2018 Aug; 32(4):319-328. PubMed ID: 29951944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
    Lee L; Horowitz J; Frenneaux M
    Eur Heart J; 2004 Apr; 25(8):634-41. PubMed ID: 15084367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The metabolic approach in patients with heart failure: effects on left ventricle remodeling.
    Tang WH
    Curr Pharm Des; 2009; 15(8):850-6. PubMed ID: 19275649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic Dysfunction in Heart Failure: Diagnostic, Prognostic, and Pathophysiologic Insights From Metabolomic Profiling.
    Hunter WG; Kelly JP; McGarrah RW; Kraus WE; Shah SH
    Curr Heart Fail Rep; 2016 Jun; 13(3):119-31. PubMed ID: 27216948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of Metabolic Flexibility in the Failing Heart.
    Karwi QG; Uddin GM; Ho KL; Lopaschuk GD
    Front Cardiovasc Med; 2018; 5():68. PubMed ID: 29928647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic remodelling in heart failure.
    Bertero E; Maack C
    Nat Rev Cardiol; 2018 Aug; 15(8):457-470. PubMed ID: 29915254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The adrenergic-fatty acid load in heart failure.
    Opie LH; Knuuti J
    J Am Coll Cardiol; 2009 Oct; 54(18):1637-46. PubMed ID: 19850204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ablation of cardiac TIGAR preserves myocardial energetics and cardiac function in the pressure overload heart failure model.
    Okawa Y; Hoshino A; Ariyoshi M; Kaimoto S; Tateishi S; Ono K; Uchihashi M; Iwai-Kanai E; Matoba S
    Am J Physiol Heart Circ Physiol; 2019 Jun; 316(6):H1366-H1377. PubMed ID: 30901275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic Modulators in Heart Disease: Past, Present, and Future.
    Lopaschuk GD
    Can J Cardiol; 2017 Jul; 33(7):838-849. PubMed ID: 28279520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine.
    Stanley WC; Marzilli M
    Fundam Clin Pharmacol; 2003 Apr; 17(2):133-45. PubMed ID: 12667223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endogenous activation of mitochondrial KATP channels protects human failing myocardium from hydroxyl radical-induced stunning.
    Maack C; Dabew ER; Hohl M; Schäfers HJ; Böhm M
    Circ Res; 2009 Oct; 105(8):811-7. PubMed ID: 19729596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of trimetazidine on carnitine palmitoyltransferase-1 in the rat heart.
    Kennedy JA; Horowitz JD
    Cardiovasc Drugs Ther; 1998 Sep; 12(4):359-63. PubMed ID: 9825181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sepsis Care Pathway 2019.
    Labib A
    Qatar Med J; 2019; 2019(2):4. PubMed ID: 31763206
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.